Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Inclusion Criteria: 1. Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent； 2. BMI ≥28 kg/m2； 3. A self-reported change in body weight no more than 5% within 90 days before screening. Exclusion Criteria: 1. History of type 1 and type 2 diabetes; 2. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device; 3. History or presence of chronic or acute pancreatitis; 4. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma; 5. A history or presence of suspected depression or other mental disorders; 6. Patient Health Questionnaire-9 score of ≥15 at screening 7. Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening; 8. History of malignant neoplasms within the past 5 years prior to screening;